4 results on '"Miao, Qianwei"'
Search Results
2. The mechanism of lauric acid-modified protein nanocapsules escape from intercellular trafficking vesicles and its implication for drug delivery.
- Author
-
Jiang, Lijuan, Liang, Xin, Liu, Gan, Zhou, Yun, Ye, Xinyu, Chen, Xiuli, Miao, Qianwei, Gao, Li, Zhang, Xudong, and Mei, Lin
- Subjects
AUTOPHAGY ,NANOCAPSULES ,ENDOCYTOSIS ,VESICLES (Cytology) ,LAURIC acid - Abstract
Protein nanocapsules have exhibited promising potential applications in the field of protein drug delivery. A major issue with various promising nano-sized biotherapeutics including protein nanocapsules is that owing to their particle size they are subject to cellular uptake via endocytosis, and become entrapped and then degraded within endolysosomes, which can significantly impair their therapeutic efficacy. In addition, many nano-sized biotherapeutics could be also sequestered by autophagosomes and degraded through the autolysosomal pathway. Thus, a limiting step in achieving an effective protein therapy is to facilitate the endosomal escape and auto-lysosomal escape to ensure cytosolic delivery of the protein drugs. Here, we prepared a protein nanocapsule based on BSA (nBSA) and the BSA nanocapsules modified with a bilayer of lauric acid (LA-nBSA) to investigate the escape effects from the endosome and autophagosome. The size distribution of nBSA and LA-nBSA analyzed using DLS presents a uniform diameter centered at 10 nm and 16 nm. The data also showed that FITC-labeled nBSA and LA-nBSA were taken up by the cells mainly through Arf-6-dependent endocytosis and Rab34-mediated macropinocytosis. In addition, LA-nBSA could efficiently escape from endosomal before the degradation in endo-lysosomes. Autophagy could also sequester the LA-nBSA through p62 autophagosome vesicles. These two types of nanocapsules underwent different intracellular destinies and lauric acid (LA) coating played a vital role in intracellular particle retention. In conclusion, the protein nanocapsules modified with LA could enhance the protein nanocapsules escape from intercellular trafficking vesicles, and protect the protein from degradation by the lysosomes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
- Author
-
Li L, Miao Q, Meng F, Li B, Xue T, Fang T, Zhang Z, Zhang J, Ye X, Kang Y, Zhang X, Chen Q, Liang X, Chen H, and Zhang X
- Subjects
- Animals, B7-H1 Antigen metabolism, CD8-Positive T-Lymphocytes metabolism, Cell Line, Cell Membrane metabolism, Cyclophosphamide pharmacology, Genetic Engineering methods, HEK293 Cells, Humans, Immune Checkpoint Inhibitors immunology, Immunoglobulin G metabolism, Immunotherapy methods, Mice, Mice, Inbred C57BL, Antibodies immunology, Drug Carriers chemistry, Neoplasms immunology, Neoplasms therapy, Receptors, IgG immunology, Receptors, IgG metabolism
- Abstract
Immune checkpoint blockade therapies, especially those targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) have achieved impressive clinical responses in multiple types of cancers. To optimize the therapeutic effect of the checkpoint antibodies, many strategies including targeting delivery, controlled release, and cellular synthesis have been developed. However, within these strategies, antibodies were attached to drug carriers by chemical bonding, which may affect the steric configuration and function of the antibodies. Herein, we prepared cluster of differentiation 64 (CD64), a natural catcher of the fragment crystalline (Fc) of monomeric immunoglobulin G (IgG), and over-expressed it on the cell membrane nanovesicles (NVs) as PD-L1 antibody delivery vehicle (CD64-NVs-aPD-L1), which was employed to disrupt the PD-1/PD-L1 immunosuppressive signal axis for boosting T cell dependent tumor elimination. Meanwhile, chemical immunomodulatory drug cyclophosphamide (CP) was also encapsulated in the vesicle (CD64-NVs-aPD-L1-CP), to simultaneously restrain the regulatory T cells (Tregs) and invigorate Ki67
+ CD8+ T cells, then further enhance their anti-tumor ability. Methods : The cell membrane NVs overexpressing CD64 were incubated with PD-L1 antibody and chemotherapeutic agent CP to prepare CD64-NVs-aPD-L1-CP. Results: The CD64-NVs-aPD-L1-CP could simultaneously interrupt the immunosuppressive effect of PD-L1 and decrease the inhibition of Tregs, leading to tumor growth suppression and survival time extension. Conclusion: CD64-NVs are charismatic carriers to achieve both checkpoint blockade and immunomodulatory drugs for combined cancer immunotherapy., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)- Published
- 2021
- Full Text
- View/download PDF
4. Surgical Tumor-Derived Personalized Photothermal Vaccine Formulation for Cancer Immunotherapy.
- Author
-
Ye X, Liang X, Chen Q, Miao Q, Chen X, Zhang X, and Mei L
- Subjects
- Animals, Breast Neoplasms immunology, Breast Neoplasms pathology, Cancer Vaccines chemistry, Cancer Vaccines immunology, Cell Membrane drug effects, Cell Membrane immunology, Disease Models, Animal, Drug Compounding, Female, Melanoma, Experimental immunology, Melanoma, Experimental pathology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Nanoparticles chemistry, Phosphorus chemistry, Quantum Dots chemistry, Tumor Cells, Cultured, Breast Neoplasms therapy, Cancer Vaccines therapeutic use, Immunotherapy, Melanoma, Experimental therapy, Phototherapy, Precision Medicine
- Abstract
Personalized cancer vaccines show great potential in cancer immunotherapy by inducing an effective and durable antitumor response. However, the limitation of neoantigen identification, low immunogenicity, and weak immune response hamper the development of personalized cancer vaccines. The surgically removed tumor contains tumor antigens specific to the patient, which provides a promising source for personalized cancer vaccines. Here, we utilized the surgically removed tumor to prepare a personalized photothermal vaccine combined with the PD-1 checkpoint blockade antibody to prevent tumor relapse and metastasis. Black phosphorus quantum dot nanovesicles (BPQD-CCNVs) coated with surgically removed tumor cell membrane were prepared and loaded into a thermosensitive hydrogel containing GM-CSF and LPS. The sustained release of GM-CSF from the hypodermic injection of Gel-BPQD-CCNVs effectively recruited dendritic cells to capture tumor antigen. NIR irradiation and LPS stimulated the expansion and activation of DCs, which then traveled to the lymph nodes to present antigen to CD8
+ T cells. Moreover, the combination with PD-1 antibody significantly enhanced tumor-specific CD8+ T cell elimination of the surgical residual and lung metastatic tumor. Hence, our work may provide a promising strategy for the clinical development of a personalized cancer vaccine.- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.